Skip to content

Oncotelic Therapeutics, Inc.: 10-Q filed 2026-08-13

What Oncotelic Therapeutics, Inc. reported in its quarterly report filed 2026-08-13 (fiscal Q2 2026): 32 published measures, 93 facts as tagged in accession 0001493152-26-037857.

This filing

Form
10-Q (quarterly report)
Filed
2026-08-13
Fiscal period
fiscal Q2 2026
Accession
0001493152-26-037857 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Oncotelic Therapeutics, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2026-06-30394,750,732USD
At 2025-12-31393,088,242USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2026-06-30131,311,353USD
At 2025-12-31131,356,683USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2026-06-30264,561,051USD
At 2025-12-31262,760,595USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2026-04-01 to 2026-06-30388,147USD91
2026-01-01 to 2026-06-30-1,805,629USD181
2025-01-01 to 2025-12-31249,300,000USD365
2025-04-01 to 2025-06-30277,856USD91
2025-01-01 to 2025-06-30-20,860USD181

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2026-01-01 to 2026-06-30-434,440USD181
2025-01-01 to 2025-06-30-293,106USD181

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2026-04-01 to 2026-06-30250,000USD91
2026-01-01 to 2026-06-30250,000USD181

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2026-01-01 to 2026-06-30531,597USD181
2025-01-01 to 2025-06-30295,000USD181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2026-06-30209,433,535USD
At 2025-12-31211,239,164USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2026-04-01 to 2026-06-30447,386,505shares91
2026-01-01 to 2026-06-30445,596,158shares181
2025-04-01 to 2025-06-30408,292,720shares91
2025-01-01 to 2025-06-30407,860,290shares181

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2026-04-01 to 2026-06-30467,914,165shares91
2026-01-01 to 2026-06-30445,596,158shares181
2025-04-01 to 2025-06-30452,809,058shares91
2025-01-01 to 2025-06-30407,860,290shares181

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2026-04-01 to 2026-06-300USD/shares91
2026-01-01 to 2026-06-300USD/shares181
2025-04-01 to 2025-06-300USD/shares91
2025-01-01 to 2025-06-300USD/shares181

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2026-04-01 to 2026-06-300USD/shares91
2026-01-01 to 2026-06-300USD/shares181
2025-04-01 to 2025-06-300USD/shares91
2025-01-01 to 2025-06-300USD/shares181

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2026-01-01 to 2026-06-302,372,257USD181

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2026-04-01 to 2026-06-30-843,565USD91
2026-01-01 to 2026-06-30-2,696,950USD181
2025-04-01 to 2025-06-30-65,969USD91
2025-01-01 to 2025-06-30-167,066USD181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2026-06-301,460,742USD
At 2025-12-311,198,252USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2026-06-3017,906,958USD
At 2025-12-3118,143,278USD

Goodwill carrying amount

Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.

PeriodValueUnitDays
At 2026-06-302,788,230USD
At 2025-12-312,788,230USD
At 2024-12-312,788,230USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2026-06-302,058USD
At 2025-12-3151,324USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2026-04-01 to 2026-06-301,093,565USD91
2026-01-01 to 2026-06-302,946,950USD181
2025-04-01 to 2025-06-3065,969USD91
2025-01-01 to 2025-06-30167,066USD181

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2026-04-01 to 2026-06-30345USD91
2026-01-01 to 2026-06-301,140USD181
2025-04-01 to 2025-06-30297USD91
2025-01-01 to 2025-06-30594USD181

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2026-06-30457,012,796shares
At 2025-12-31442,596,856shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2026-06-3050,556,882USD
At 2025-12-3147,095,219USD

Total equity including noncontrolling interests

Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.

PeriodValueUnitDays
At 2026-06-30263,439,379USD
At 2026-03-31262,211,541USD
At 2025-12-31261,731,559USD
At 2025-06-307,393,895USD
At 2025-03-317,183,446USD
At 2024-12-317,477,512USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2026-06-301,252,670USD
At 2025-12-311,038,071USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2026-04-01 to 2026-06-30341,011USD91
2026-01-01 to 2026-06-30-1,898,265USD181
2026-01-01 to 2026-03-31-2,239,276USD90
2025-04-01 to 2025-06-30210,449USD91
2025-01-01 to 2025-06-30-153,815USD181
2025-01-01 to 2025-03-31-364,264USD90

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2026-04-01 to 2026-06-301,093,220USD91
2026-01-01 to 2026-06-302,945,810USD181
2025-04-01 to 2025-06-3065,672USD91
2025-01-01 to 2025-06-30166,472USD181

Nonoperating interest expense

Interest expense presented outside operating results. It differs from total interest expense when some borrowing cost is classified as operating or capitalized.

PeriodValueUnitDays
2026-04-01 to 2026-06-30318,292USD91
2026-01-01 to 2026-06-30614,103USD181
2025-04-01 to 2025-06-30207,780USD91
2025-01-01 to 2025-06-30411,579USD181

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2026-04-01 to 2026-06-301,184,576USD91
2026-01-01 to 2026-06-30798,685USD181
2025-04-01 to 2025-06-30276,418USD91
2025-01-01 to 2025-06-3013,251USD181

Deferred income tax expense or benefit

The deferred portion of income tax expense or benefit, arising from timing differences. It is not tax paid in the period.

PeriodValueUnitDays
2025-01-01 to 2025-12-31111,600,000USD365

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2026-01-01 to 2026-06-30163,597USD181
2025-01-01 to 2025-06-30175,650USD181

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2026-04-01 to 2026-06-306,630USD91
2026-01-01 to 2026-06-306,630USD181

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2026-01-01 to 2026-06-30-49,266USD181

Inspect the source

Entity
Oncotelic Therapeutics, Inc. / CIK 0000908259
Captured
2026-09-20T05:05:47.535Z
SEC response SHA-256
6c0026f9e455c874f284117994b59a028bad3a82bccf268424724837d8c3b9db

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000908259.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))